CONDUCTING COMPARATIVE CLINICAL-PHARMACOLOGICAL EVALUATION PHARMACOTHERAPY PREPARATIONS OF BOTULINUM TOXIN A IN CHILDREN WITH CEREBRAL PALSY SYNDROME WITH MARKED SPASTICITY

2019 ◽  
Vol 25 (5-6) ◽  
pp. 293-302
Author(s):  
Anna Petrovna Solovieva ◽  
Vladimir Vladimirovich Arkhipov ◽  
Dmitry Vladimirovich Goryachev
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Pharmacoeconomic Analysis ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Clinical Pharmacological Evaluation

The original methodology for retrospective clinical studies on the criteria of “efficiency/safety” and pharmacoeconomics on the criteria of “cost/effectiveness”is proposed. The results of a retrospective study of medical records in 169 patients with cerebral palsy, which showed that the use of drugs botulinum toxin type A is an important integral component in the long-term treatment of children with spastic forms of cerebral palsy. Presents the results of pharmacoeconomic analysis of the treatment of the syndrome of spasticity in cerebral palsy when used in the complex treatment of Dysport, Botox and Xeomin.

Long-term treatment with botulinum toxin type A in hemifacial spasm

Toxicon ◽  
2008 ◽  
Vol 51 ◽  
pp. 30-31
Author(s):  
Kollewe Katja ◽  
Krampfl Klaus ◽  
Bigalke Hans ◽  
Dengler Reinahrd ◽  
Mohammadi Bahram
Keyword(s):  
Botulinum Toxin ◽  
Hemifacial Spasm ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

2008 ◽  
Vol 23 (10) ◽  
pp. 1353-1360 ◽  
Author(s):  
Mitchell F. Brin ◽  
Cynthia L. Comella ◽  
Joseph Jankovic ◽  
Francis Lai ◽  
Markus Naumann ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Protection Assay ◽  
Long Term Treatment

1.310 Botulinum toxin type A in simple motor tics: Analysis of long-term treatment

2007 ◽  
Vol 13 ◽  
pp. S79
Author(s):  
J. Rath ◽  
D. Tavy ◽  
A. Wertenbroek ◽  
T. van Woerkom ◽  
S. de Bruijn
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Simple Motor ◽  
Long Term Treatment ◽  
Motor Tics

Botulinum toxin type A in simple motor tics: Short-term and long-term treatment-effects

2010 ◽  
Vol 16 (7) ◽  
pp. 478-481 ◽  
Author(s):  
Judith J.G. Rath ◽  
Dénes L.J. Tavy ◽  
Agnes A.A.C.M. Wertenbroek ◽  
Theodoor C.A.M. van Woerkom ◽  
Sebastiaan F.T.M. de Bruijn
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Short Term ◽  
Simple Motor ◽  
Long Term Treatment ◽  
Motor Tics

scholarly journals Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department

2015 ◽  
Vol 72 (12) ◽  
pp. 1069-1073
Author(s):  
Aleksandra Tomic ◽  
Balsa Vujovic ◽  
Marina Svetel ◽  
Natasa Dragasevic-Miskovic ◽  
Igor Petrovic ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Rating Scales ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Spastic Torticollis

Background/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic acetylcholine release with subsequent relaxation of abnormally contracting muscles. It is an effective and well tolerated treatment with long-term benefit in a variety of movement disorders and other neurological and non-neurological disturbances. The aim of our study was to present our experience with BTX type A in treatment of different forms of focal dystonias. ?ethods. ? hundred of patients with different focal dystonias (spastic torticollis, blepharospasm and graphospasm) from the Botulinum Toxin Outpatients Department, Clinic for Neurology, Clinical Center of Serbia, were included in the study. All the patients were examined and rated at baseline visit prior to BTX application and on the following visit, after 3-4 months, using self-assessment improvement questionnaire and standardized rating scales. Results. The improvement of ? 50% was presented in 68.2% of all (199) the analyzed applications. Independent predictors of good response to the therapy (improvement ? 50%) were male sex (p = 0.011), the presence of sensory trick (p = 0.013) and the total number of BTX applications (p = 0.002). The patients with spastic torticollis and blepharospasm showed a statistically significantly better BTX effect (improvement 57.3 ? 27.5% and 54.1 ? 28.3%), respectively than the graphospasm group (26.7 ? 25.6%). Most of the patients did not have therapy complications (81.4% and 72% in two applications). Side effects in the remaining patients (muscle weakness, dysphagia, ptosis, double vision, neck weakness and lacrimal dysfunction) lasted for 28.3 ? 18.6 days after the first treatment and 32.5 ? 36.2 days after the second one. Conclusion. BTX is safe and highly effective in long-term treatment of patients with different forms of focal dystonia, with only mild and well-tolerated side-effects.

Long-term treatment of spasticity with botulinum toxin type A

Toxicon ◽  
2008 ◽  
Vol 51 ◽  
pp. 31-32
Author(s):  
Mohammadi Bahram ◽  
Baloush Shokufeh ◽  
Krampfl Klaus ◽  
Bigalke Hans ◽  
Dengler Reinhard ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment

Experience with long-term treatment with albumin-supplemented botulinum toxin type A

2009 ◽  
Vol 116 (4) ◽  
pp. 437-441 ◽  
Author(s):  
Bahram Mohammadi ◽  
Katja Kollewe ◽  
Maresa Wegener ◽  
Hans Bigalke ◽  
Reinhard Dengler
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Botulinum toxin A in the treatment of blepharospasm: a 10-year experience

2005 ◽  
Vol 63 (2a) ◽  
pp. 221-224 ◽  
Author(s):  
Laura Silveira-Moriyama ◽  
Lilian R. Gonçalves ◽  
Hsin Fen Chien ◽  
Egberto R. Barbosa
Keyword(s):  
Botulinum Toxin ◽  
Adverse Effects ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Term Effect ◽  
Secondary Resistance ◽  
School Of Medicine ◽  
Long Term Effect

To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.

Sign in / Sign up

Export Citation Format

Share Document